AWH - Aspira Women's Health Inc. Stock Price, Fair Value and News

2.97USD-0.10 (-3.26%)Market Closed

Market Summary

USD2.97-0.10

Market Closed

-3.26%

AWH Stock Price

View Fullscreen

AWH RSI Chart

AWH Valuation

Market Cap

36.7M

Price/Earnings (Trailing)

-2.2

Price/Sales (Trailing)

4.01

EV/EBITDA

-1.87

Price/Free Cashflow

-3.99

AWH Price/Sales (Trailing)

AWH Profitability

EBT Margin

-208.82%

Return on Equity

705.71%

Return on Assets

-266.53%

Free Cashflow Yield

-25.04%

AWH Fundamentals

AWH Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

-1.07%

Rev. Growth (Qtr)

-3.92%

AWH Earnings

Earnings (TTM)

-16.7M

Earnings Growth (Yr)

32.72%

Earnings Growth (Qtr)

34.36%

Breaking Down AWH Revenue

Last 7 days

-3.4%

Last 90 days

-35.5%

Trailing 12 Months

-31.1%

How does AWH drawdown profile look like?

AWH Financial Health

Current Ratio

1.03

Debt/Equity

-0.6

Debt/Cashflow

-6.4

AWH Investor Care

Shares Dilution (1Y)

48.20%

Diluted EPS (TTM)

-1.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.6M	9.0M	9.2M	9.2M
2022	7.2M	7.5M	7.9M	8.2M
2021	4.9M	6.0M	6.4M	6.8M
2020	5.0M	4.6M	4.5M	4.7M
2019	3.2M	3.6M	4.2M	4.5M
2018	1.5M	2.0M	2.5M	3.1M
2017	477.0K	632.0K	787.0K	942.0K
2016	1.7M	1.9M	2.2M	322.0K
2015	3.2M	3.4M	3.4M	2.2M
2014	2.5M	2.5M	2.5M	2.5M
2013	2.1M	2.1M	2.1M	2.6M
2012	1.8M	1.8M	1.8M	2.1M
2011	1.4M	1.5M	1.7M	1.9M
2010	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aspira Women's Health Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	sandford nicole	bought	-	-	2,400	president & ceo
Dec 06, 2023	merchant minh hoang	sold	-3,302	3.37	-980	secretary & general counsel
Dec 06, 2023	sandford nicole	bought	16,800	3.36	5,000	president & ceo
Nov 17, 2023	merchant minh hoang	acquired	-	-	10,000	secretary & general counsel
Nov 17, 2023	hombeck torsten	acquired	-	-	30,000	chief financial officer
Sep 08, 2023	hombeck torsten	bought	9,657	4.3	2,246	chief financial officer
Aug 29, 2023	sandford nicole	acquired	-	-	26,367	president and ceo
Aug 29, 2023	sandford nicole	acquired	-	-	26,467	president & ceo
Aug 28, 2023	jordan veronica gh	acquired	-	-	7,045	-
Aug 28, 2023	fralick celeste rachelle	acquired	-	-	13,252	-

Which funds bought or sold AWH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-117	369	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	4.08	-42.00	158	-%
May 10, 2024	Castleview Partners, LLC	unchanged	-	-1,289	4,080	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-59.54	-6,325	2,809	-%
May 10, 2024	BlackRock Inc.	unchanged	-	-61,511	194,575	-%
May 10, 2024	VANGUARD GROUP INC	added	41.53	60,254	859,962	-%
May 10, 2024	JPMORGAN CHASE & CO	added	0.14	-2,023	6,439	-%
May 07, 2024	Quantum Private Wealth, LLC	added	4.51	-42,141	162,496	0.06%
May 07, 2024	M&T Bank Corp	unchanged	-	-14,699	46,497	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling AWH?

Are funds buying AWH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AWH

No. of Funds

Unveiling Aspira Women's Health Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	schultz eric adam	4.41%	543,998	SC 13G/A
Dec 26, 2023	schultz eric adam	263%	543,998	SC 13G
Jul 26, 2023	schuler jack w	18.7%	1,883,656	SC 13D/A
Feb 15, 2023	seamark capital lp	5.1%	-	SC 13G/A
Aug 29, 2022	schuler jack w	20.8%	25,885,120	SC 13D/A
Feb 16, 2022	seamark capital lp	5.0%	-	SC 13G/A
Feb 14, 2022	drysdale robert h	-	0	SC 13G
Jan 13, 2022	sharman tanya schuler	5.3%	5,943,881	SC 13D/A
Dec 30, 2021	schuler tino hans	4.3%	4,829,019	SC 13D/A
Dec 30, 2021	schuler henri george	8.2%	9,207,779	SC 13D/A

Recent SEC filings of Aspira Women's Health Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	DEFA14A	DEFA14A
May 06, 2024	4	Insider Trading
Apr 26, 2024	424B5	Prospectus Filed
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	8-K	Current Report
Apr 25, 2024	EFFECT	EFFECT
Apr 22, 2024	S-3	S-3
Apr 11, 2024	EFFECT	EFFECT
Apr 11, 2024	424B3	Prospectus Filed
Apr 10, 2024	CORRESP	CORRESP

Peers (Alternatives to Aspira Women's Health Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	186.2B	23.7B	0.67%	7.73%	42.31	7.85	-8.94%	-35.91%
A	42.5B	6.7B	-1.54%	13.33%	34.41	6.32	-2.81%	-6.58%
IDXX	41.4B	3.7B	-3.64%	3.26%	47.73	11.1	8.57%	23.94%
DGX	15.3B	9.3B	4.06%	4.31%	18.14	1.65	-3.29%	6.68%
MEDP	12.4B	2.0B	-1.35%	90.01%	39.58	6.3	25.57%	21.62%
CRL	11.9B	4.1B	-10.52%	23.52%	27.01	2.88	0.49%	-11.59%
NTRA	11.7B	1.2B	-1.92%	86.70%	-32.11	9.71	39.26%	33.08%
EXAS	10.0B	2.5B	-27.12%	-31.26%	-41.6	3.94	15.21%	53.51%
MID-CAP
NEOG	2.7B	929.2M	-4.60%	-27.46%	1.7K	2.87	28.93%	111.61%
GH	2.4B	603.7M	1.41%	-29.38%	-5.16	3.94	25.21%	30.68%
SMALL-CAP
CDNA	772.4M	275.1M	11.46%	29.10%	-4.22	2.81	-13.93%	-126.97%
ACRS	83.4M	31.1M	2.52%	-85.28%	-1.08	2.68	0.95%	19.75%
AWH	36.7M	9.2M	-	-31.11%	-2.2	4.01	11.85%	44.15%
APDN	3.4M	5.5M	858.97%	243.12%	-0.28	0.62	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Aspira Women's Health Inc. News

Latest updates

Aspira Women's Health Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-3.9%	2,130	2,217	2,491	2,316	2,153	2,072	2,066	1,893	1,851	1,666	1,799	1,496	1,446	1,239	746	1,220	1,308	1,285	1,142	803	922
Gross Profit	-6.9%	1,217	1,307	1,550	1,191	1,240	1,156	966	961	1,014	749	696	603	231	432	153	420	516	336	234	109	169
Operating Expenses	3.4%	5,607	5,423	5,871	6,960	6,331	9,736	9,186	10,208	9,960	10,440	8,768	6,489	6,305	4,713	3,979	4,220	3,920	4,186	4,539	3,828	2,993
S&GA Expenses	3.4%	1,760	1,702	1,772	2,562	2,888	3,950	3,580	4,497	4,877	5,083	4,018	3,108	2,843	2,152	1,733	2,115	2,076	2,425	2,780	2,364	1,596
R&D Expenses	9.7%	1,095	998	693	1,231	1,002	2,157	1,410	1,348	1,453	1,518	1,471	872	734	595	380	395	244	340	225	209	125
EBITDA Margin	-0.4%	-2.06*	-2.05*	-2.08*	-2.18*	-2.30*	-2.40*	-2.53*	-2.62*	-2.77*	-2.94*	-3.15*	-3.82*	-4.05*	-	-	-	-	-	-	-	-
Interest Expenses	-83.3%	2.00	12.00	8.00	26.00	27.00	18.00	-10.00	-18.00	-13.00	-14.00	3.00	-24.00	-4.00	5.00	1.00	8.00	20.00	34.00	-2.00	7.00	3.00
EBT Margin	-0.3%	-2.09*	-2.08*	-2.12*	-2.22*	-2.34*	-2.43*	-2.56*	-2.65*	-2.81*	-2.98*	-3.20*	-3.88*	-4.11*	-	-	-	-	-	-	-	-
Net Income	34.4%	-3,089	-4,706	-2,317	-6,578	-4,591	-7,783	-8,243	-9,268	-8,961	-9,707	-7,074	-5,920	-6,081	-4,287	-3,831	-3,706	-3,387	-3,820	-4,314	-3,716	-2,820
Net Income Margin	8.0%	-1.82*	-1.98*	-2.35*	-3.16*	-3.65*	-4.35*	-4.84*	-4.86*	-4.65*	-4.49*	-3.91*	-4.08*	-3.85*	-3.37*	-	-	-	-	-	-	-
Free Cashflow	-407.1%	-10,200	3,321	3,413	-5,714	-7,150	-7,568	-6,327	-10,255	-7,679	-8,019	-6,585	-5,296	-4,979	-3,211	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-27.7%	6,262	8,662	7,720	11,496	17,373	23,942	24,016	30,861	41,079	48,047	55,829	62,297	19,605	21,265	13,091	10,353	13,828	16,533	18,152	8,254	11,408
Current Assets	-30.3%	5,280	7,572	6,862	10,528	16,309	22,976	22,956	29,800	40,005	47,188	54,907	61,373	18,603	20,251	12,690	9,986	13,410	16,050	17,565	7,576	10,788
Cash Equivalents	-49.1%	2,597	5,100	4,246	7,535	13,306	20,551	20,480	26,855	37,430	44,870	52,993	59,369	16,631	18,836	10,935	8,132	11,703	14,636	16,179	6,174	9,360
Inventory	-24.6%	227	301	272	302	316	280	191	189	174	137	101	71.00	30.00	45.00	66.00	63.00	25.00	29.00	90.00	98.00	92.00
Net PPE	-25.3%	165	221	261	305	368	417	438	480	464	498	546	533	583	593	360	318	353	399	472	531	608
Liabilities	-7.4%	8,627	9,321	8,248	10,669	10,394	12,764	9,894	9,117	10,907	9,543	8,991	9,972	9,886	6,715	5,824	5,051	5,090	4,706	4,786	4,617	4,256
Current Liabilities	-0.8%	5,119	5,162	5,374	5,911	5,527	7,297	7,044	6,139	7,840	6,409	5,791	6,148	6,000	4,615	4,199	3,985	3,978	3,537	3,561	3,336	2,964
Short Term Borrowings	770.1%	670	77.00	306	535	764	-	260	519	779	-	204	408	611	476	587	194	303	192	191	190	189
Long Term Debt	17.5%	1,430	1,217	1,334	2,204	2,315	2,426	2,536	2,646	2,718	2,768	2,818	2,718	3,477	1,678	1,615	1,050	1,099	1,148	1,196	1,244	1,292
LT Debt, Current	-56.1%	166	378	259	442	403	343	283	223	201	200	199	201	645	-	-	-	193	-	-	-	-
LT Debt, Non Current	17.5%	1,430	1,217	1,334	2,204	2,315	2,426	2,536	2,646	2,718	2,768	2,818	2,718	3,477	1,678	1,615	1,050	1,099	1,148	1,196	1,244	1,292
Shareholder's Equity	-Infinity%	-2,365	-	-	827	6,979	11,178	14,122	21,744	30,172	38,504	46,838	52,325	9,719	14,550	7,267	5,302	8,738	11,827	13,366	3,637	7,152
Retained Earnings	-0.6%	-518,300	-515,214	-507,282	-504,965	-501,613	-497,022	-489,239	-480,996	-471,728	-462,767	-453,060	-445,986	-440,066	-433,985	-429,698	-425,867	-422,161	-418,774	-414,954	-410,640	-406,924
Additional Paid-In Capital	0.3%	515,927	514,544	506,745	505,784	508,584	508,192	503,249	502,628	501,893	501,159	499,786	498,199	449,680	448,431	436,864	431,072	430,802	430,504	428,226	414,202	414,001
Shares Outstanding	3.5%	10,645	10,287	8,473	8,330	8,306	8,296	7,483	7,476	7,476	7,394	7,354	7,244	6,975	-	-	-	-	-	-	-	-
Float	-	-	-	17,677	-	-	-	50,184	-	-	-	477,546	-	-	-	290,268	-	-	-	47,232	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-406.8%	-10,188	3,321	3,417	-5,706	-7,076	-7,515	-6,304	-10,173	-7,649	-8,001	-6,490	-5,255	-4,756	-3,067	-3,410	-3,501	-2,871	-3,442	-3,544	-3,108	-2,298
Share Based Compensation	-38.0%	422	681	488	133	420	546	610	838	590	1,178	1,282	489	427	411	441	269	300	296	413	184	262
Cashflow From Investing	-Infinity%	-12.00	-	-4.00	-8.00	-74.00	-53.00	-23.00	-82.00	-30.00	-18.00	-95.00	-41.00	-223	-144	-100	-23.00	-12.00	-39.00	-34.00	-48.00	-55.00
Cashflow From Financing	-77.0%	961	4,176	134	-55.00	-94.00	7,639	-48.00	-70.00	-11.00	146	209	48,034	2,774	11,112	6,313	-47.00	-50.00	1,938	13,583	-30.00	-47.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AWH Income Statement

2023-12-31

Consolidated Statements Of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Revenue	$ 9,154	$ 8,184
Cost of revenue:
Cost of revenue	3,892	3,861
Gross profit	5,262	4,323
Operating expenses:
Research and development	4,035	5,917
Sales and marketing	7,812	14,915
General and administrative	12,267	14,629
Total operating expenses	24,114	35,461
Loss from operations	(18,852)	(31,138)
Other income (expense), net:
Change in fair value of warrant liabilities	629	1,704
Interest income, net	48	17
Forgiveness of DECD loan	1,000
Other income (expense), net	485	(468)
Total other income (expense), net	2,162	1,253
Net loss	$ (16,690)	$ (29,885)
Net loss per share - basic	$ (1.81)	$ (3.85)
Net loss per share - diluted	$ (1.81)	$ (3.85)
Weighted average common shares used to compute basic net loss per common share	9,233,306	7,769,109
Weighted average common shares used to compute diluted net loss per common share	9,233,306	7,769,109
Product [Member]
Revenue:
Revenue	$ 9,153	$ 7,970
Cost of revenue:
Cost of revenue	3,892	3,694
Genetics [Member]
Revenue:
Revenue	$ 1	214
Cost of revenue:
Cost of revenue		$ 167

AWH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,597	$ 13,306
Accounts receivable, net of reserves of $15 and $9, as of December 31, 2023 and December 31, 2022, respectively	1,459	1,245
Prepaid expenses and other current assets	997	1,442
Inventories	227	316
Total current assets	5,280	16,309
Property and equipment, net	165	368
Right-of-use assets	528	282
Restricted cash	258	251
Other assets	31	163
Total assets	6,262	17,373
Current liabilities:
Accounts payable	1,261	881
Accrued liabilities	2,863	3,402
Current portion of long-term debt	166	403
Short-term debt	670	764
Current maturities of lease liabilities	159	77
Total current liabilities	5,119	5,527
Non-current liabilities:
Long-term debt	1,430	2,315
Non-current maturities of lease liabilities	427	272
Warrant liabilities	1,651	2,280
Total liabilities	8,627	10,394
Commitments and contingencies (Note 6)
Stockholders’ (deficit) equity:
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 10,645,049 and 8,306,326 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	11	8
Additional paid-in capital	515,927	508,584
Accumulated deficit	(518,303)	(501,613)
Total stockholders’ (deficit) equity	(2,365)	6,979
Total liabilities and stockholders’ (deficit) equity	$ 6,262	$ 17,373

About Aspira Women's Health Inc.

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

CEO	Ms. Nicole Sandford CPA
WEBSITE	https://aspirawh.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	85

Aspira Women's Health Inc. Frequently Asked Questions

What is the ticker symbol for Aspira Women's Health Inc.? What does AWH stand for in stocks?

AWH is the stock ticker symbol of Aspira Women's Health Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aspira Women's Health Inc. (AWH)?

As of Thu May 09 2024, market cap of Aspira Women's Health Inc. is 37.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers. The fair value of Aspira Women's Health Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aspira Women's Health Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AWH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aspira Women's Health Inc. a good stock to buy?

The fair value guage provides a quick view whether AWH is over valued or under valued. Whether Aspira Women's Health Inc. is cheap or expensive depends on the assumptions which impact Aspira Women's Health Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AWH.

What is Aspira Women's Health Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, AWH's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 4.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AWH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aspira Women's Health Inc.'s stock?

In the past 10 years, Aspira Women's Health Inc. has provided -0.234 (multiply by 100 for percentage) rate of return.